August 9/Oslo, Norway/Press Release -- Aker BioMarine Antarctic (Aker BM) announced the U.S. FDA has accepted with no objections the notification of its independent GRAS determination for Superba™ Krill oil for use as a food ingredient.  This acceptance, plus FDA's recent acknowledgement of Aker BM's New Dietary Ingredient Notification (NDIN), provides regulatory support for existing and prospective customers of  Superba™ Krill oil for inclusion in new products and in new markets.

"Consumer safety and trust is paramount in the natural ingredients arena, and Aker BioMarine Antarctic has developed an extensive safety dossier for Superba™ Krill oil.  The FDA's earlier acknowledgement of our NDIN was important for our existing and future customers to introduce Superba™ products in all supplement channels, while the new self-affirmed GRAS Notice acceptance solidly opens the door to applications in the food and beverage industries as well," stated Matts Johansen, EVP Sales and Marketing. 
 
"We are very pleased to offer our customers the support of these two important safety and regulatory compliant distinctions.  Helping our customers confidently launch new Superba™ Krill oil-based supplements and food and beverage products is essential to our business development," Johansen concluded.
 
Nils Hoem, PhD, Chief Scientist at Aker BM, added, "We have clinical studies underway and in development with our customers internationally.  Seeking to substantiate the health benefits of krill oil for joint health, mental acuity, heart health issues and other emerging areas of study will help our customers deliver krill products with validated health benefits, expanding the scope of the omega-3 market today."